Xenon Pharmaceuticals Inc. (XENE) on GreekSoup https://greeksoup.ai/stocks/us/xene/ Every dated entry in the public record on Xenon Pharmaceuticals Inc.: results, filings, insider trades and the rest, from the filings, the last 90 days. en Wed, 28 Oct 2026 00:00:00 +0000 Xenon Pharmaceuticals Inc.: short interest 7,348,577 shares at the 15 October 2026 settlement, 3.95 days to coverhttps://greeksoup.ai/stocks/us/xene/short-interest/us:XENE:short-interest:2026-10-15:5abd2b489aThu, 15 Oct 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Xenon Pharmaceuticals Inc.: Kelly Thomas Patrick (Chief Financial Officer) bought 15,000 shares at $37.32 on 30 September 2026, $559,740https://greeksoup.ai/stocks/us/xene/insiders/us:XENE:insider:2026-10-01:2af7ee67f7Thu, 01 Oct 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Xenon Pharmaceuticals Inc.: Mortimer Ian (PRESIDENT & CEO) bought 30,000 shares at $37.38 on 30 September 2026, $1.1 millionhttps://greeksoup.ai/stocks/us/xene/insiders/us:XENE:insider:2026-10-01:5b9e63d355Thu, 01 Oct 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Xenon Pharmaceuticals Inc.: short interest 6,041,487 shares at the 30 September 2026 settlement, 1.58 days to coverhttps://greeksoup.ai/stocks/us/xene/short-interest/us:XENE:short-interest:2026-09-30:318171d28bWed, 30 Sep 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Xenon Pharmaceuticals Inc.: short interest 6,444,815 shares at the 15 September 2026 settlement, 12.22 days to coverhttps://greeksoup.ai/stocks/us/xene/short-interest/us:XENE:short-interest:2026-09-15:7faff984f8Tue, 15 Sep 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Xenon Pharmaceuticals Inc.: Kenney Christopher John (Chief Medical Officer) sold 6,368 shares (under a trading plan set in advance) at $60.17 on 28 August 2026, $383,145https://greeksoup.ai/stocks/us/xene/insiders/us:XENE:insider:2026-08-31:66a3edd665Mon, 31 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Xenon Pharmaceuticals Inc.: Kenney Christopher John (Chief Medical Officer) sold 700 shares (under a trading plan set in advance) at $60.98 on 28 August 2026, $42,684https://greeksoup.ai/stocks/us/xene/insiders/us:XENE:insider:2026-08-31:08d3503bb0Mon, 31 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Xenon Pharmaceuticals Inc.: short interest 6,344,135 shares at the 31 August 2026 settlement, 9.09 days to coverhttps://greeksoup.ai/stocks/us/xene/short-interest/us:XENE:short-interest:2026-08-31:a68372e973Mon, 31 Aug 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Xenon Pharmaceuticals Inc.: Form 144, CHRISTOPHER KENNEY plans to sell 7,068 shares worth $437,721 around 28 August 2026https://greeksoup.ai/stocks/us/xene/planned-sales/us:XENE:planned-sale:2026-08-28:fd0e5ddef4Fri, 28 Aug 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Xenon Pharmaceuticals Inc.: short interest 5,668,994 shares at the 14 August 2026 settlement, 9.16 days to coverhttps://greeksoup.ai/stocks/us/xene/short-interest/us:XENE:short-interest:2026-08-14:c9d4266293Fri, 14 Aug 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Xenon Pharmaceuticals Inc.: Form 144, STEVEN GANNON plans to sell 10,000 shares worth $640,553 around 11 August 2026https://greeksoup.ai/stocks/us/xene/planned-sales/us:XENE:planned-sale:2026-08-13:8b03e9f693Thu, 13 Aug 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Xenon Pharmaceuticals Inc.: Schedule 13G/A filed by Wellington Management Group LLP, 1.5% of the classhttps://greeksoup.ai/stocks/us/xene/holders/us:XENE:schedule-13:2026-08-13:0d1c695a56Thu, 13 Aug 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Xenon Pharmaceuticals Inc.: Gannon Steven (Director) sold 10,000 shares at $64.06 on 11 August 2026, $640,550https://greeksoup.ai/stocks/us/xene/insiders/us:XENE:insider:2026-08-13:a57e5189ffThu, 13 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Xenon Pharmaceuticals Inc.: Schedule 13G/A filed by FMR LLC, 10.3% of the classhttps://greeksoup.ai/stocks/us/xene/holders/us:XENE:schedule-13:2026-08-07:d735b4f431Fri, 07 Aug 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Xenon Pharmaceuticals Inc. Q2 FY2026 results: revenue $0, net income -$111 millionhttps://greeksoup.ai/stocks/us/xene/results/fy2026-q2/us:XENE:result:2026-08-06:819c006ef6Thu, 06 Aug 2026 00:00:00 +0000ResultsResults. The filing. The page on GreekSoup.

]]> Xenon Pharmaceuticals Inc. filed 10-Q: 10-qhttps://greeksoup.ai/stocks/us/xene/filings/us:XENE:filing:2026-08-06:1ee4d26452Thu, 06 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Xenon Pharmaceuticals Inc. filed 8-K: results of operations, regulation fd disclosurehttps://greeksoup.ai/stocks/us/xene/filings/us:XENE:filing:2026-08-06:f0a94bc7f1Thu, 06 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Xenon Pharmaceuticals Inc.: Schedule 13G/A filed by FMR LLC, 9.9% of the classhttps://greeksoup.ai/stocks/us/xene/holders/us:XENE:schedule-13:2026-08-06:7fd5c6984dThu, 06 Aug 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Xenon Pharmaceuticals Inc.: short interest 5,384,476 shares at the 31 July 2026 settlement, 7.33 days to coverhttps://greeksoup.ai/stocks/us/xene/short-interest/us:XENE:short-interest:2026-07-31:c60061c34eFri, 31 Jul 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]>